5‐HT2 receptor antagonism in dysthymic disorder: a double‐blind placebo‐controlled study with ritanserin

Bersani, G.; Pozzi, F.; Marini, Stefano; Grispini, A.; Pasini, Augusto; Ciani, N

doi:10.1111/j.1600-0447.1991.tb05533.x

Cited by 80 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is suggested, therefore, that there is no involvement of 5-HT2 receptors in the effect of fluvoxamine. There are some reports that a 5-HT2 antagonist was effective in another depression model (namely, the response rate of differential-reinforcement-of-lowrate schedule (14), and the antagonist has therapeutic benefits in patients with dysthymia (15). However, the present results suggest that the 5-HT2 receptors were not involved in either production of the immobility itself or the effect of fluvoxamine on immobility.…”

contrasting

confidence: 54%

See 1 more Smart Citation

Neither the 5-HT1A- nor the 5-HT2-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Forced-Swimming-Induced Immobility in Mice

Egawa

Ichimaru

Imanishi

et al. 1995

Japanese Journal of Pharmacology

View full text Add to dashboard Cite

ABSTRACT-The effect of fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, was studied in the forced-swimming test, a model of depression, in mice. Fluvoxamine at 60 mg/kg, p.o. significantly decreased the immobility time in the forced-swimming test. A similar effect was observed by the selective norepinephrine reuptake inhibitor desipramine at the same dose. Furthermore, the suppression of immobility time was slightly potentiated by repeated administration of fluvoxamine, and a significant effect was observed at 30 mg/kg, p.o. The effect of fluvoxamine on forced-swimming was unaffected by the 5-HT2 antagonist ritanserin. On the other hand, the 5-HT1A antagonist Selective serotonin (5-HT) reuptake inhibitors (SSRIs; fluvoxamine, fluoxetine, etc.) have established their status as effective antidepressants with effects comparable to the more traditionally used tricyclic and tetracyclic antidepressants (1). Furthermore, it is recognized that the binding sites for the antidepressant imipramine are the 5-HTreuptake pumps (2) and that 5-HT2 receptors are also down-regulated by the repeated administration of antidepressants (3). These lines of evidence support the 5-HT theory of depressive illness, and it is apparent, therefore, that malfunction of 5-HT transmission is involved in depressive illness.The forced-swimming test has been used elsewhere to evaluate the efficacy of antidepressants (4). There is, however, few reports about the effect of fluvoxamine on the forced-swimming test (5). Furthermore, there is no report about the subchronic effect of fluvoxamine on this model or which 5-HT receptor subtype mediates the effect of fluvoxamine on immobility.In the present experiments, therefore, we investigated Male ICR strain mice weighing 20-30 g (Nihon SLC, Atsugi) were used in the experiment. All animals were housed in the animal rooms (temperature, 20-25C; °hu-midity, 60 ±5%; light on at 7 a.m.; light off at 7 p.m.) for

show abstract

contrasting

confidence: 54%

“…In fact, we have already found that the 5-HTIA antagonist NAN-190 completely suppressed the effect of fluvoxamine on the marble-burying behavior test in mice (15). However, NAN-190 potentiated the effect of fluvoxamine on forced-swimming-induced immobility in the present study.…”

contrasting

confidence: 49%

Neither the 5-HT1A- nor the 5-HT2-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Forced-Swimming-Induced Immobility in Mice

Egawa

Ichimaru

Imanishi

et al. 1995

Japanese Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…This was confirmed by overcoming immobility with muscarinic receptor antagonists (e.g., atropine and pirenzepine) and 5-HT2 receptor-selective inhibitors (e.g., ritanserin and cyproheptadine). These findings provide support for the potential clinical relevance of this model because antimuscarinic agents (e.g., scopolamine [33]) and 5-HT2 receptor antagonists have both been used to treat depression [34,35]. The diminished motivation is also improved by certain antipsychotic drugs (clozapine and olanzapine) with superior efficacy against negative symptoms, including suicide attempts/ideation.…”

Section: Anhedonia Apathy and Avolition Versus Immobility And Diminmentioning

confidence: 66%

Crossing the Worm-Brain Barrier by Using Caenorhabditis elegans to Explore Fundamentals of Human Psychiatric Illness

Dwyer¹

2017

Complex Psychiatry

View full text Add to dashboard Cite

Endophenotypes and Research Domain Criteria (RDoC) represent recent efforts to deconvolute psychiatric illnesses into fundamental symptom clusters or biological markers more closely linked to genetic influences. By taking this one step farther, these biomarkers can be reduced to protophenotypes - endophenotypes conserved during evolution - with counterparts in lower organisms including Caenorhabditis elegans and Drosophila. Striking conservation in C. elegans of genes that increase the risk for mental illness bolsters the relevance of this model system for psychiatric research. Here, I review the characterization of several protophenotypes that are relevant for asociality, avolition/anhedonia, prepulse inhibition, and anorexia. Interestingly, the analogous behavioral defects in C. elegans are also corrected by psychotropic drugs used to treat the corresponding symptoms in man and/or are mediated by the same neurotransmitters. Overall, there is much we can learn about the complex human brain by studying simpler nervous systems directing evolutionarily conserved behaviors. The potential for generating important new insights from model organisms appears limitless when we begin to recognize the vestiges of evolution in ourselves.

show abstract

“…In particular, the efficacy of antidepressants in the treatment of pure dysthymia (31)(32)(33)(34) and double depression (20,(35)(36)(37)(38) has been demonstrated. For example, Thase and colleagues compared sertraline and imipramine in the treatment of outpatients with dysthymia (n = 410) (33).…”

Section: Pharmacotherapy Acute Treatmentmentioning

confidence: 99%

Breaking the Myths: New Treatment Approaches for Chronic Depression

Michalak

Lam

2002

Can J Psychiatry

View full text Add to dashboard Cite

Background: Chronic depressive disorders are common, accounting for approximately one-third of all cases of depression and posing a major public health problem. In the past, chronic depression has been thought to be treatment-resistant, and evidence suggests that it is currently underdiagnosed, misdiagnosed, and suboptimally treated. Objectives: To review the subtypes of chronic depression and the evidence-base concerning their optimal treatment and to discuss some key clinical issues and areas of future research. Methods: We identified key studies and randomized controlled trials (RCTs) by systematically searching electronic databases and hand searching specialist journals and bibliographies. Results: Chronic depressive disorders respond well to standard pharmacologic interventions in the acute and maintenance phases of treatment. Standard psychotherapies alone may not be efficacious for chronic depression (especially dysthymia). Recent evidence suggests that treatment combining psychotherapy and medications may be superior to either treatment alone. Conclusions: Chronic depressive disorders are amenable to treatment, provided that intervention is both thorough and intensive. Although our knowledge about the optimal treatment of chronic depression has developed rapidly, changes in clinical practice have been slower to evolve. Further research is required to assess the effectiveness of multimodal interventions for chronic depression in more naturalistic settings.

show abstract

5‐HT₂ receptor antagonism in dysthymic disorder: a double‐blind placebo‐controlled study with ritanserin

Cited by 80 publications

References 20 publications

Neither the 5-HT1A- nor the 5-HT2-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Forced-Swimming-Induced Immobility in Mice

Neither the 5-HT1A- nor the 5-HT2-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Forced-Swimming-Induced Immobility in Mice

Crossing the Worm-Brain Barrier by Using <b><i>Caenorhabditis elegans</i></b> to Explore Fundamentals of Human Psychiatric Illness

Breaking the Myths: New Treatment Approaches for Chronic Depression

Contact Info

Product

Resources

About